Cargando…

The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis

This review aims to assess the efficacy and safety of low-dose Tripterygium wilfordii Hook F (TWHF) in treating type 2 diabetic nephropathy (DN) and provide high-level evidence supporting its normalized application. METHODS: Seven electronic databases were queried to locate trials that qualify. Rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yixuan, Lu, Meiqi, Feng, Yiting, Gao, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803423/
https://www.ncbi.nlm.nih.gov/pubmed/36596065
http://dx.doi.org/10.1097/MD.0000000000032504
_version_ 1784861882160513024
author Chen, Yixuan
Lu, Meiqi
Feng, Yiting
Gao, Qing
author_facet Chen, Yixuan
Lu, Meiqi
Feng, Yiting
Gao, Qing
author_sort Chen, Yixuan
collection PubMed
description This review aims to assess the efficacy and safety of low-dose Tripterygium wilfordii Hook F (TWHF) in treating type 2 diabetic nephropathy (DN) and provide high-level evidence supporting its normalized application. METHODS: Seven electronic databases were queried to locate trials that qualify. Randomized controlled trials (RCTs) about low-dose TWHF long-term treatment of type 2 DN are included. After data extraction and quality evaluation of the clinical studies that met the inclusion criteria, a meta-analysis was performed using RevMan 5.4 and Stata 14. RESULTS: A total of 23 RCTs were included. For the patients in the trial group, the effective rate [confidence interval (CI), odd ratio] [odd ratio = 1.38, 95% CI (1.22–1.56), P < .001], albumin [standard mean difference (SMD) = 0.58, 95% CI (0.18–0.98), P = .004], 24-hour urine total protein [SMD = −1.329, 95% CI = (−1.647 to −1.012), P < .001], serum creatinine [SMD = −0.64, 95% CI = (−0.86 to −0.31), P < .001], and the untoward effect [RR = 2.43 95% CI = (1.23–4.82), P = .01] were significantly higher than those in the control group. However, in white blood cell [Weighted mean difference = −0.27, 95% CI (−0.54 to 0.01), P = .06] and blood urea nitrogen [Weighted mean difference = −0.11, 95% CI (−0.42 to 0.21), z = 0.67, P = .50], none of the differences were significant compared with the control group. CONCLUSION: This suggests that low-dose TWHF positively affects patients with type 2 DN after a long course of treatment. Although there are some side effects, symptoms can improve after medication suspension or symptomatic treatment. Limited by the methodological quality of the included studies, this conclusion needs to be verified by more large-sample RCTs with rigorous design and long-term follow-up.
format Online
Article
Text
id pubmed-9803423
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98034232023-01-03 The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis Chen, Yixuan Lu, Meiqi Feng, Yiting Gao, Qing Medicine (Baltimore) 5200 This review aims to assess the efficacy and safety of low-dose Tripterygium wilfordii Hook F (TWHF) in treating type 2 diabetic nephropathy (DN) and provide high-level evidence supporting its normalized application. METHODS: Seven electronic databases were queried to locate trials that qualify. Randomized controlled trials (RCTs) about low-dose TWHF long-term treatment of type 2 DN are included. After data extraction and quality evaluation of the clinical studies that met the inclusion criteria, a meta-analysis was performed using RevMan 5.4 and Stata 14. RESULTS: A total of 23 RCTs were included. For the patients in the trial group, the effective rate [confidence interval (CI), odd ratio] [odd ratio = 1.38, 95% CI (1.22–1.56), P < .001], albumin [standard mean difference (SMD) = 0.58, 95% CI (0.18–0.98), P = .004], 24-hour urine total protein [SMD = −1.329, 95% CI = (−1.647 to −1.012), P < .001], serum creatinine [SMD = −0.64, 95% CI = (−0.86 to −0.31), P < .001], and the untoward effect [RR = 2.43 95% CI = (1.23–4.82), P = .01] were significantly higher than those in the control group. However, in white blood cell [Weighted mean difference = −0.27, 95% CI (−0.54 to 0.01), P = .06] and blood urea nitrogen [Weighted mean difference = −0.11, 95% CI (−0.42 to 0.21), z = 0.67, P = .50], none of the differences were significant compared with the control group. CONCLUSION: This suggests that low-dose TWHF positively affects patients with type 2 DN after a long course of treatment. Although there are some side effects, symptoms can improve after medication suspension or symptomatic treatment. Limited by the methodological quality of the included studies, this conclusion needs to be verified by more large-sample RCTs with rigorous design and long-term follow-up. Lippincott Williams & Wilkins 2022-12-30 /pmc/articles/PMC9803423/ /pubmed/36596065 http://dx.doi.org/10.1097/MD.0000000000032504 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5200
Chen, Yixuan
Lu, Meiqi
Feng, Yiting
Gao, Qing
The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
title The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
title_full The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
title_fullStr The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
title_full_unstemmed The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
title_short The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
title_sort effect and safety of low-dose tripterygium wilfordii in patients with type 2 diabetic nephropathy: a meta-analysis
topic 5200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803423/
https://www.ncbi.nlm.nih.gov/pubmed/36596065
http://dx.doi.org/10.1097/MD.0000000000032504
work_keys_str_mv AT chenyixuan theeffectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis
AT lumeiqi theeffectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis
AT fengyiting theeffectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis
AT gaoqing theeffectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis
AT chenyixuan effectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis
AT lumeiqi effectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis
AT fengyiting effectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis
AT gaoqing effectandsafetyoflowdosetripterygiumwilfordiiinpatientswithtype2diabeticnephropathyametaanalysis